Developer docs
API playgroundTry for free, no card

Search company profiles

BioVie

Full company profile

uuid0000ysi

Namestring
BioVie
Legal namestring
BioVie Inc.
Company typeenum
Public
Founded yearint
2019
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCarson City, United States
HQ citystring
Carson City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceuticals, neurodegenerative disease therapies, liver disease therapeutics, anti-inflammatory small molecules, specialty pharmaceutical R&D
Industry3 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Biopharmaceuticals
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage pharmaceutical company. Revenue will come from commercialization of drug candidates bezisterim (NE3107) for Alzheimer's, Parkinson's, Long COVID and BIV201 for ascites/cirrhosis upon regulatory approval. No products currently approved or marketed.

bioviepharma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

BioVie is a clinical-stage pharmaceutical company developing two drug candidates: bezisterim (NE3107), an orally administered anti-inflammatory and insulin-sensitizing small molecule being studied for Alzheimer's disease, Parkinson's disease, and Long COVID; and BIV201, a continuous infusion formulation of terlipressin delivered via a portable pump for outpatient treatment of refractory ascites due to liver cirrhosis. Neither candidate is yet approved or commercially marketed, so revenue will come from future commercialization upon regulatory approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 68% slowing of cognitive decline after 6 months of bezisterim treatment in Alzheimer's patients
+4 more records
Product overview1 text field

BioVie is a clinical-stage pharmaceutical company developing drug therapies for neurological, neurodegenerative, and liver diseases. The company's product portfolio consists of two main drug candidates: Bezisterim (NE3107), an oral anti-inflammatory insulin sensitizer being developed for Alzheimer's disease, Parkinson's disease, and Long COVID; and BIV201, a continuous infusion formulation of terlipressin for treating refractory ascites associated with liver cirrhosis. Both drug candidates target inflammatory pathways believed to be central to disease progression.

Product and service2 records
1Bezisterim (NE3107)
CategoryInvestigational small-molecule drug
Description

BioVie's lead asset: a novel, orally administered small molecule that is both anti-inflammatory and insulin-sensitizing. It selectively inhibits inflammation-driven ERK- and NF-κB-stimulated inflammatory mediators, including TNF-α, without inhibiting their homeostatic functions. Currently being studied for Alzheimer's disease, Parkinson's disease, and neurological symptoms of Long COVID.

2BIV201
CategoryInvestigational infusion drug therapy
Description

A novel continuous infusion formulation of terlipressin delivered via a small, portable pump for outpatient treatment of refractory ascites due to liver cirrhosis. Holds US Orphan drug designation for ascites and hepatorenal syndrome, and FDA Fast Track status for ascites. Phase 2b data showed greater than 50% reduction in ascites fluid buildup.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Option Therapeutics (Spinout)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

BioVie plans to spin out its BIV201 ascites program into a newly filed public company called Option Therapeutics, needing to raise $25 million to fund a required Phase III trial after observing greater than 50% reduction in ascites fluid buildup in terminated Phase IIb data.

fiercepharma.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage NASDAQ-listed CNS biotech developing small molecules for Alzheimer's, Parkinson's, Rett syndrome, and other neurodegenerative indications. Highly comparable to BioVie in size, stage, mechanism novelty, and indication overlap.

2Cassava Sciences
TypeDirect peer
Description

Clinical-stage small-cap biotech developing simufilam for Alzheimer's disease. Comparable to BioVie in market cap range, single-asset CNS focus, and dependence on pivotal-stage data catalysts.

TypeEmerging player
Description

Clinical-stage biotech developing sabirnetug (ACU193) for early Alzheimer's disease. Comparable as a small-cap, CNS-focused, anti-amyloid-mechanism competitor, though BioVie targets a non-amyloid mechanism.

TypeEmerging player
Description

European clinical-stage biotech developing small molecules targeting neuroinflammation in Alzheimer's (varoglutamstat). Closely parallels BioVie's inflammation-driven CNS hypothesis and pipeline stage.

TypeEmerging player
Description

Clinical-stage biotech developing protein-based therapies for neurodegenerative diseases including Parkinson's and Alzheimer's. Comparable as a small-cap CNS-focused player, though operating with a different therapeutic modality.

TypeEmerging player
Description

CNS-focused biotech with FDA-approved products (Auvelity, Sunosi) in neurology and psychiatry. Comparable as a small-cap CNS commercial-stage peer, providing a benchmark for BioVie's potential transition from clinical to commercial stage.

TypeBroad incumbent
Description

Specialty pharmaceutical company that markets Terlivaz (terlipressin) — the FDA-approved formulation of the same active ingredient in BioVie's BIV201 — for hepatorenal syndrome. Direct competitive incumbent in BioVie's ascites franchise.

TypeBroad incumbent
Description

CNS-focused biopharma with FDA-approved Zurzuvae (zuranolone) for postpartum depression. Comparable as a small-mid cap CNS company with approved and pipeline neurology/psychiatry assets, broader in scale and commercial maturity than BioVie.

TypeBroad incumbent
Description

Clinical-stage CNS and lysosomal disease biotech developing therapies for Parkinson's, Alzheimer's, and ALS. Comparable indication overlap with BioVie, larger in scale, and a useful public-market reference for CNS biotech valuation.

TypeEmerging player
Description

Clinical-stage small-cap biotech developing CT1812 for Alzheimer's disease and dementia with Lewy bodies. Comparable to BioVie in market cap, stage, and CNS focus on neurodegenerative diseases.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioVie

Clinical-Stage Biopharmaceuticalsbioviepharma.com

BioVie firmographics

Firmographics
Name
BioVie
Legal name
BioVie Inc.
Website
https://bioviepharma.com
Company type
Public
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

BioVie industry classification

Industry
Product category
Clinical-Stage Biopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals

Keywords

  • Clinical-stage biopharmaceuticals
  • Neurodegenerative disease therapies
  • Liver disease therapeutics
  • Anti-inflammatory small molecules
  • Specialty pharmaceutical R&D

Where BioVie is headquartered

Location

Headquarters

HQ city
Carson City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

BioVie business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Drug Development and Commercialization: Pre-revenue clinical-stage pharmaceutical company. Revenue will come from commercialization of drug candidates bezisterim (NE3107) for Alzheimer's, Parkinson's, Long COVID and BIV201 for ascites/cirrhosis upon regulatory approval. No products currently approved or marketed.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

BioVie product offering

Product offering

Core offering

BioVie is a clinical-stage pharmaceutical company developing two drug candidates: bezisterim (NE3107), an orally administered anti-inflammatory and insulin-sensitizing small molecule being studied for Alzheimer's disease, Parkinson's disease, and Long COVID; and BIV201, a continuous infusion formulation of terlipressin delivered via a portable pump for outpatient treatment of refractory ascites due to liver cirrhosis. Neither candidate is yet approved or commercially marketed, so revenue will come from future commercialization upon regulatory approval.

Product overview

BioVie is a clinical-stage pharmaceutical company developing drug therapies for neurological, neurodegenerative, and liver diseases. The company's product portfolio consists of two main drug candidates: Bezisterim (NE3107), an oral anti-inflammatory insulin sensitizer being developed for Alzheimer's disease, Parkinson's disease, and Long COVID; and BIV201, a continuous infusion formulation of terlipressin for treating refractory ascites associated with liver cirrhosis. Both drug candidates target inflammatory pathways believed to be central to disease progression.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bezisterim (NE3107) BioVie's lead asset: a novel, orally administered small molecule that is both anti-inflammatory and insulin-sensitizing. It selectively inhibits inflammation-driven ERK- and NF-κB-stimulated inflammatory mediators, including TNF-α, without inhibiting their homeostatic functions. Currently being studied for Alzheimer's disease, Parkinson's disease, and neurological symptoms of Long COVID.
  • BIV201 A novel continuous infusion formulation of terlipressin delivered via a small, portable pump for outpatient treatment of refractory ascites due to liver cirrhosis. Holds US Orphan drug designation for ascites and hepatorenal syndrome, and FDA Fast Track status for ascites. Phase 2b data showed greater than 50% reduction in ascites fluid buildup.

Quantifiable outcome

  • 68% slowing of cognitive decline after 6 months of bezisterim treatment in Alzheimer's patients
  • +4 more outcomes

Companies that use BioVie

Customer profile

Segments4 records

Ideal customer profiles3 records

BioVie technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

BioVie partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Option Therapeutics (Spinout)coreStrategic or Co-development PartnerBioVie plans to spin out its BIV201 ascites program into a newly filed public company called Option Therapeutics, needing to raise $25 million to fund a required Phase III trial after observing greater than 50% reduction in ascites fluid buildup in terminated Phase IIb data.

Scale indicators14 records

Recent moves7 records

Expansion highlights5 records

BioVie competitors and assessment

Company assessment

Direct peers

  • Anavex Life Sciences: Clinical-stage NASDAQ-listed CNS biotech developing small molecules for Alzheimer's, Parkinson's, Rett syndrome, and other neurodegenerative indications. Highly comparable to BioVie in size, stage, mechanism novelty, and indication overlap.
  • Cassava Sciences: Clinical-stage small-cap biotech developing simufilam for Alzheimer's disease. Comparable to BioVie in market cap range, single-asset CNS focus, and dependence on pivotal-stage data catalysts.

Emerging players

  • Acumen Pharmaceuticals: Clinical-stage biotech developing sabirnetug (ACU193) for early Alzheimer's disease. Comparable as a small-cap, CNS-focused, anti-amyloid-mechanism competitor, though BioVie targets a non-amyloid mechanism.
  • Vivoryon Therapeutics: European clinical-stage biotech developing small molecules targeting neuroinflammation in Alzheimer's (varoglutamstat). Closely parallels BioVie's inflammation-driven CNS hypothesis and pipeline stage.
  • Prothena Corporation: Clinical-stage biotech developing protein-based therapies for neurodegenerative diseases including Parkinson's and Alzheimer's. Comparable as a small-cap CNS-focused player, though operating with a different therapeutic modality.
  • Axsome Therapeutics: CNS-focused biotech with FDA-approved products (Auvelity, Sunosi) in neurology and psychiatry. Comparable as a small-cap CNS commercial-stage peer, providing a benchmark for BioVie's potential transition from clinical to commercial stage.
  • Cognition Therapeutics: Clinical-stage small-cap biotech developing CT1812 for Alzheimer's disease and dementia with Lewy bodies. Comparable to BioVie in market cap, stage, and CNS focus on neurodegenerative diseases.

Broad incumbents

  • Mallinckrodt Pharmaceuticals: Specialty pharmaceutical company that markets Terlivaz (terlipressin) — the FDA-approved formulation of the same active ingredient in BioVie's BIV201 — for hepatorenal syndrome. Direct competitive incumbent in BioVie's ascites franchise.
  • Sage Therapeutics: CNS-focused biopharma with FDA-approved Zurzuvae (zuranolone) for postpartum depression. Comparable as a small-mid cap CNS company with approved and pipeline neurology/psychiatry assets, broader in scale and commercial maturity than BioVie.
  • Denali Therapeutics: Clinical-stage CNS and lysosomal disease biotech developing therapies for Parkinson's, Alzheimer's, and ALS. Comparable indication overlap with BioVie, larger in scale, and a useful public-market reference for CNS biotech valuation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

BioVie social profiles

Digital presence

BioVie financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioVie leadership team

Management profile

Number of profiles

Profiles12 records

BioVie funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioVie M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioVie

What does BioVie do?

BioVie is a clinical-stage pharmaceutical company developing two drug candidates: bezisterim (NE3107), an orally administered anti-inflammatory and insulin-sensitizing small molecule being studied for Alzheimer's disease, Parkinson's disease, and Long COVID; and BIV201, a continuous infusion formulation of terlipressin delivered via a portable pump for outpatient treatment of refractory ascites due to liver cirrhosis. Neither candidate is yet approved or commercially marketed, so revenue will come from future commercialization upon regulatory approval.

Is BioVie a public or private company?

BioVie is a public company. It is classified as public and is currently operating.

When was BioVie founded?

BioVie was founded in 2019. It employs 11 to 50 people.

Where is BioVie based?

BioVie is headquartered in Carson City, United States, in the North America region.

How does BioVie make money?

One revenue line is on record: drug Development and Commercialization.

Who are BioVie's main competitors?

Direct peers on record are Anavex Life Sciences and Cassava Sciences. Emerging players are Acumen Pharmaceuticals, Vivoryon Therapeutics, Prothena Corporation, Axsome Therapeutics and Cognition Therapeutics. Broad incumbents are Mallinckrodt Pharmaceuticals, Sage Therapeutics and Denali Therapeutics.

Does BioVie have an API?

No public API is recorded for BioVie.

What industry is BioVie in?

BioVie's product category is Clinical-Stage Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewBioVie 3Q 2026: EPS ($0.68) — 10-Q SummaryBioVie reported a Q3 2026 diluted EPS of -$0.68, a 30.6% improvement from -$0.98, with a net loss of $5.61 million. The loss widened due to higher R&D expenses from the Long COVID Phase 2 program and lower interest income, offset by reduced amortization. The company remains pre-revenue.TradingViewBioVie Raises $4.74 Million in Registered Offering and Private Warrant PlacementBioVie closed a registered direct offering and private warrant placement on November 5, 2026, raising approximately $4.74 million in gross proceeds. The company will use net proceeds for working capital and general corporate purposes, and paid Alliance Global Partners a 7% cash fee plus expense reimbursements.Seeking AlphaBioVie launches $4.74M direct offering and concurrent private placementBioVie launched a $4.74M registered direct offering of 2,962,500 shares at $1.60 per share, with a concurrent private placement of warrants exercisable at $1.70. The company will use net proceeds for working capital and general corporate purposes, with closing expected on November 5, 2026.Stock TitanBioVie prices stock offering; expects ~$4.74M gross proceedsBioVie Inc. priced a registered direct offering and concurrent private placement for approximately $4.74 million in gross proceeds. The offering includes 2,962,500 shares at $1.60 per share and warrants exercisable at $1.70. Closing is expected on November 5, 2026, with net proceeds for working capital and general corporate purposes.Business & FinancialBiovie Selected For Late-Breaking Oral Presentation Of Bezisterim Long COVID Data At The 4Th Long COVID International Conference 2026BioVie will present bezisterim data at the 4th Long COVID International Conference on November 13, 2026. The Phase 2 ADDRESS-LC trial showed a consistent trend toward improvement across most measures, with pre-specified subgroup analyses revealing statistically significant benefits in patients with severe baseline fatigue, post-exertional malaise, or cognitive impairment.Defense WorldBioVie Inc. (NASDAQ:BIVI) Shares Shorted: Short Interest Down 34.5% in OctoberBioVie's short interest fell 34.5% to 544,444 shares as of October 15, with 7.5% of shares short sold. CEO Cuong Do bought 15,210 shares, and Renaissance Technologies raised its stake by 142.4%. Analysts have downgraded the stock to a sell rating.American Banking and Market NewsBioVie Inc. (NASDAQ:BIVI) Shares Shorted: Short Interest Down 34.5% in OctoberBioVie's short interest fell 34.5% to 544,444 shares as of October 15th, with 7.5% of shares sold short. CEO Cuong Do bought 15,210 shares at $2.08, and Renaissance Technologies raised its stake by 142.4%. Analysts have a consensus "Sell" rating.EIN PresswireNew Phase 2 Data on Bezisterim for the Treatment of Long COVID | Psychiatric TimesBioVie announced phase 2 trial results for bezisterim in long COVID, showing safety and symptom gains. Patients with severe fatigue, PEM, or cognitive impairment saw the greatest benefits, with no serious adverse events. The data supports a confirmatory phase 3 study.American Banking and Market NewsBioVie (NASDAQ:BIVI) Cut to Sell at Wall Street ZenWall Street Zen downgraded BioVie to a sell rating, and Weiss Ratings reaffirmed a sell (e+). The company reported a Q2 loss of $0.70 per share, missing the $0.52 consensus, and CEO Cuong Do bought 15,210 shares at $2.08 each.American Banking and Market NewsBioVie (NASDAQ:BIVI) Downgraded by Wall Street Zen to SellWall Street Zen downgraded BioVie to a sell rating, and Weiss Ratings reaffirmed a sell (e+). The company reported a Q2 loss of $0.70 per share, missing the $0.52 consensus, and insiders bought 23,280 shares in the quarter. Renaissance Technologies increased its stake by 142.4%.